E-mail：hygj@ncpc.biz
Website：m.tibetgrz.cn/en
Add：217-1,East Heping Road, Shijiangzhuang, Hebei P.R.China.050015
Fill A Vacancy in China
The important project of Recombinant Human Anti Rabies Virus Monoclonal Antibody Injection from NCPC is supported by Ministry of Science and Technology, has been developed in 6 years, carried out the clinical trial for about 3 years, the results of the accomplished phase Ia of clinical trial indicate that the tolerance for the volunteers to Recombinant Human Anti Rabies Virus Monoclonal Antibody Injection is good, the adverse reaction after injection hasn’t been observed during the trial, the drug safety to human has been obtained the preliminary confirmation.